CD274 and esophageal squamous cell carcinoma: The ESCORT‐1st study, a phase III, prospective, multicenter, randomized controlled, double‐blind trial, included advanced/metastatic ESCC patients demonstrated a higher 3‐year OS rate in the camrelizumab plus chemotherapy group compared with the chemotherapy group, regardless of PD‐L1 status, extending survival beyond 3 years in 25% of patients [104].